Severity of the Omicron <scp>SARS‐CoV</scp>‐2 variant compared with the previous lineages: A systematic review
Maryam Arabi, Yousef Al‐Najjar, Nada Mhaimeed, Mohammad Salameh, Pradipta Paul, Jamal AlAnni, Ali Abdelati, Ibrahim Laswi, Bushra Khanjar, Dana Al‐Ali, Abdallah Elshafeey, Omar Mhaimeed, Zain Burney, Ashton D’Souza, Pratyaksha Sinha, Mohammad Bhatti, Krishnadev V. Pillai, Moayad Homssi, Khalifa Bshesh, Lina Yagan, Dalia Zakaria
Abstract
The Omicron variant was first detected in October 2021, which evolved from the original SARS-CoV-2 strain and was found to possess many mutations. Immune evasion was one of the notable consequences of these mutations. Despite Omicron exhibiting increased transmissibility, the rates of hospitalizations and deaths among patients infected with this variant were substantially lower when compared to other strains. However, concluding that the Omicron variant is less severe than other variants of SARS-CoV-2 requires consideration of multiple factors, including the vaccination status of infected patients as well as any previous infections with other variants. This review compiled data about any reported indicators of severity in Omicron-infected patients, including studies comparing Omicron with other variants while adjusting for confounders. A comprehensive search was conducted using different databases to target any studies about Omicron. In total, 62 studies met our inclusion criteria and were included in this study. Many studies reported a significantly reduced risk of hospitalization, ICU admission, need for oxygenation/ventilation, and death in Omicron-infected patients compared to patients infected with other variants, such as Delta. Some studies, however, reported comparable severity in Omicron infected patients as to other variants emphasizing a substantial risk for severe illness. Furthermore, the COVID-19 vaccines were less effective against Omicron relative to previous lineages, except after receiving the booster dose. One study recommended vaccination during pregnancy, which may help prevent future cases of severe SARS-CoV-2 pneumonia in neonates and young infants due to the transfer of humoral response from the mother.